Skip to content

Clinical trials

Cardiomyopathy, Dilated trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cardiomyopathy, Dilated Country / region: Italy Clear all

17 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20071
20081
20091
20111
20121
20141
20151
20161
20183
20202
20231
20242
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting5
Unknown status5
Completed4
Terminated2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
LoneStar Heart, Inc.2
Ancora Heart, Inc.1
Azienda Ospedaliera Universitaria Integrata Verona1
Azienda Ospedaliero, Universitaria Pisana1
Bambino Gesù Hospital and Research Institute1
Catholic University of the Sacred Heart1
Centro Medico Teknon1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1
IRCCS Azienda Ospedaliero-Universitaria di Bologna1
IRCCS SYNLAB SDN1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cardiomyopathy, Dilated17
Heart Failure12
Cardiomyopathies6
Cardiomyopathy, Hypertrophic3
Death, Sudden, Cardiac3
Fabry Disease2
Amyloid Neuropathies, Familial1
Arrhythmias, Cardiac1
Arrhythmogenic Right Ventricular Dysplasia1
Atrial Fibrillation1

Trials

Showing 76 to 17 of 17. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.